Search results for: Jorge Mestre-Ferrandiz
Filter search results
OHE at ISPOR May 2016: Meet the Team
19 May 2016
…Multi-Indication Pricing: Pros, Cons and its Applicability to the UK OHE Authors: Jorge Mestre-Ferrandiz and Adrian Towse Time and date: Monday 23rd May, 3:45pm. Summary: Multi-indication pricing (MIP) involves setting…
Critical Factors Affecting Pharmaceutical R&D and the Availability of New Drugs
18 June 2013
Dr Jorge Mestre-Ferrandiz, OHE’s Director of Consulting, was a recent guest lecturer at Imperial College London. His comprehensive presentation covered the gamut of issues that influence the rate and direction…
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
…Association (DIA), OHE’s Jorge Mestre-Ferrandiz presented the results of OHE research into R&D discontinuations. The reasons for discontinuation of R&D projects in the biopharmaceutical industry are often a matter of…
Evidence on Valued Based Pricing and Reimbursement Schemes
30 September 2011
At the PPRI conference in Vienna on 29-30 September, 2011, Jorge Mestre-Ferrandiz presented a poster summarising the results of a literature review on risk sharing, flexible pricing, patient access schemes…
OHE at ISPOR Washington DC (1): HTA, Evidence and Pricing
9 June 2016
…Jorge Mestre-Ferrandiz. The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics from Office of Health Economics This poster was designed by…
OHE at AES: Medicines Prices in the UK, Health Inequalities in Costa Rica
25 June 2013
OHE’s participation at the 33rd Meeting of the Spanish Health Economics Association (AES) last week reported the results of four research projects. Jorge Mestre-Ferrandiz, OHE’s Director of Consulting, presented OHE’s…
Spotlight on OHE: NICE, Biosimilars, HTA
17 June 2014
…34th Spanish Health Economics Association annual meeting, Jorge Mestre-Ferrandiz reviewed the results of the discussions of an expert panel about the role of HTA for biosimilars. Representatives from the three…
R&D Cost Drivers to be Explained by OHE Expert
18 January 2013
Jorge Mestre-Ferrandiz, lead author on OHE’s recent report on the cost of developing new drugs, will be discussing the important cost drivers at an upcoming UCL Vision seminar in London…
Spotlight on OHE: Value Footprint of Oncology Treatments, Treating Obstructive Sleep Apnoea and Sources of Motivation in Health Care Organisations
4 August 2015
…at the Spanish Health Economists Association Annual Meeting in Granada, Spain, 17-19th June 2015, OHE’s Jorge Mestre-Ferrandiz delivered a presentation on the expanding value footprint of oncology treatments. Jorge’s presentation…